DOV PHARMACEUTICAL, INC. SHAREHOLDERS APPROVE MERGER AGREEMENT AND TRANSACTION IS CONSUMATED

DOV Pharmaceutical, Inc. (DOV), a Delaware corporation previously traded on the Pink Sheets (Pink Sheets: DOVP), announced that a majority of its shareholders have voted to approve a merger agreement in connection with the  merger and acquisition of DOV by Euthymics at a special meeting held on Monday, July 19, 2010.  The acquisition price for DOV is for up to $2.0 million in cash, payable in two installments, representing a total of approximately $0.015 per share of DOV common stock. The transaction has now been consummated.

 Additional information can be found at www.euthymics.com.

Media:

BioCom Partners

Stephen Gendel, Jennifer Anderson, 212-918-4650

or

Investors:

Euthymics Bioscience, Inc.

Anthony A. McKinney, 617-674-3830